© 1998 by European Society of Cardiology
Copyright © 1998, European Society of Cardiology
Platelet aggregation in acute coronary syndromes: use of a new aggregometer with laser light scattering to assess platelet aggregability
aDepartment of Medicine (Cardiology), Teikyo University School of Medicine, Tokyo, Japan
bDepartment of Clinical and Laboratory Medicine, Yamanashi Medical University, Yamanashi, Japan
* Corresponding author. Tel.: 81 (3) 3964 1211 (ext. 1580); Fax: 81 (3) 5375 1308; E-mail: stake@blue.ocn.ne.jp
Objective: Platelet aggregation has been implicated in the pathogenesis of acute coronary syndromes. Small aggregates consisting of 
100 platelets cannot be quantified with a conventional aggregometer employing optical density. Using a recently developed aggregometer based on laser light scattering, we studied platelet aggregability in patients with acute coronary syndromes. Methods: Peripheral blood samples were obtained from 39 patients with acute myocardial infarction or unstable angina who had received no prior antiplatelet or anticoagulant therapy, to be assayed immediately using a PA-100 platelet aggregometer. Blood samples from 14 healthy volunteers were used as controls. Results: Spontaneous formation of platelet aggregates was observed only in patients with acute coronary syndromes. The size of these aggregates was small, consisting of 100 platelets (primary aggregation). Agonist-induced aggregation consisted of two phases. In the first few minutes, the number of small aggregates increased markedly (primary aggregation), followed by an increase in larger aggregates (secondary aggregation). The EC50 of epinephrine for primary aggregation was nearly 50 times lower in acute coronary patients than in controls (P<0.001), while the EC50 for secondary aggregation was only 2 times lower (P<0.001). Conclusions: Aggregometry using light scattering suggests that platelet hyperaggregability and hypersensitivity in acute coronary syndromes may occur in primary but not secondary aggregation.
KEYWORDS Atherosclerosis; Coronary disease; Ischemia; Platelets; Thrombosis
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. R Prieto, H. Ma, R. Huang, G. Khan, K. A Schwartz, E. E Hage-Korban, A. H Schmaier, J. M Davis, A. A.K Hasan, and G. S Abela Thrombostatin, a bradykinin metabolite, reduces platelet activation in a model of arterial wall injury Cardiovasc Res, March 1, 2002; 53(4): 984 - 992. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Eto, T. Isshiki, H. Yamamoto, S. Takeshita, M. Ochiai, N. Yokoyama, R. Yoshimoto, Y. Ikeda, and T. Sato AJvW-2, an Anti-vWF Monoclonal Antibody, Inhibits Enhanced Platelet Aggregation Induced by High Shear Stress in Platelet-Rich Plasma From Patients With Acute Coronary Syndromes Arterioscler Thromb Vasc Biol, April 1, 1999; 19(4): 877 - 882. [Abstract] [Full Text] [PDF]
|
|